Grisnilimab setaritox

N/A

Report date: 2023/07/12 14:57:44

Base Information

Drug NameGrisnilimab setaritox

Drug Alias NameAnti-CD7 monoclonal antibody-ricin chain A conjugateGrisnilimab WT1-ricin A

ClassificationBiologics > Protein drugs > ToxinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murine

Mechanisms of ActionT-cell antigen CD7 inhibitorsImmunosuppressants

TargetsT-cell antigen CD7

Therapy Area/IndicationsGraft vs Host Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesN/A

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive Companies +[1] N/A

Active IndicationsN/A

Inactive IndicationsGraft vs Host Disease

Other Information

ATC CodeN/A